This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/517584-secret-wepaon-antibiotic-resisant-bacteria/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Research identifies possible new secret weapon in fight against antibiotic-resistant bacteria | Research identifies possible new secret weapon in fight against antibiotic-resistant bacteria |
| (6 months later) | |
| New research into a specific mechanism by which bacteria develop resistance to antibiotics has yielded a potential game changer for next-generation drugs to win the arms race against antimicrobial resistance (AMR) in bacteria. | New research into a specific mechanism by which bacteria develop resistance to antibiotics has yielded a potential game changer for next-generation drugs to win the arms race against antimicrobial resistance (AMR) in bacteria. |
| The study, led by professor Tony Maxwell, investigated quinolone antibiotics, which are used to fight numerous bacterial infections up to and including TB (tuberculosis). | The study, led by professor Tony Maxwell, investigated quinolone antibiotics, which are used to fight numerous bacterial infections up to and including TB (tuberculosis). |
| Quinolones work by inhibiting certain enzymes in bacteria which prevent them from replicating their DNA and synthesising RNA, stopping them dead in their tracks, hence their widespread use in modern medicine. | Quinolones work by inhibiting certain enzymes in bacteria which prevent them from replicating their DNA and synthesising RNA, stopping them dead in their tracks, hence their widespread use in modern medicine. |
| But therein lies the problem, as bacterial resistance to this and other leading treatments grows worldwide, there is a gap in the medicinal arsenal for treating many particularly nasty infections. | But therein lies the problem, as bacterial resistance to this and other leading treatments grows worldwide, there is a gap in the medicinal arsenal for treating many particularly nasty infections. |
| One resistance mechanism, called pentapeptide repeat proteins (PRPs), can confer quinolone resistance to Mycobacterium tuberculosis, the bacterial mastermind behind TB. | One resistance mechanism, called pentapeptide repeat proteins (PRPs), can confer quinolone resistance to Mycobacterium tuberculosis, the bacterial mastermind behind TB. |
| John Innes Centre researchers, led by Maxwell, conducted a deep-dive investigation into these PRPs at a molecular level, to gain a better understanding of what they were up against and how they might be able to neutralise it. | John Innes Centre researchers, led by Maxwell, conducted a deep-dive investigation into these PRPs at a molecular level, to gain a better understanding of what they were up against and how they might be able to neutralise it. |
| They took a purified form of a similar bacterium, mycobacterium smegmatis, and found that a PRP called MfpA can disrupt a DNA process which is essential for quinolone to effectively target the right enzyme in the bacteria, thus shielding the bacteria from the antibiotic airstrike, so to speak. | They took a purified form of a similar bacterium, mycobacterium smegmatis, and found that a PRP called MfpA can disrupt a DNA process which is essential for quinolone to effectively target the right enzyme in the bacteria, thus shielding the bacteria from the antibiotic airstrike, so to speak. |
| “We believe this understanding will help drive new ideas for antibiotic development among academics and researchers in the pharma industry,” Maxwell said. | “We believe this understanding will help drive new ideas for antibiotic development among academics and researchers in the pharma industry,” Maxwell said. |
| Further research will develop molecular models based on MfpA's structure to create small molecules with similar functionality, with a view to preventing collusion between MfpA and the bacteria and allow next-generation antibiotics to destroy their targets. | Further research will develop molecular models based on MfpA's structure to create small molecules with similar functionality, with a view to preventing collusion between MfpA and the bacteria and allow next-generation antibiotics to destroy their targets. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |